N-(3,4-dibromophenyl)-N'-phenylthiourea

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3,4-dibromophenyl)-N'-phenylthiourea
• 英文别名: 1-(3,4-dibromophenyl)-3-phenylthiourea
• 化学式: C₁₃H₁₀Br₂N₂S
• 分子量: 386.11
• InChiKey: GCLOVZHBJSXWPL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  56.2
• 氢给体数：
  2
• 氢受体数：
  1

文献信息

• Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist
  申请人：Michel Martin

  公开号：US20050154041A1

  公开（公告）日：2005-07-14

  This invention describes a new combination for the treatment of functional bladder disorders which comprises alpha agonists and a beta-3-adrenoceptor agonist.

  本发明描述了一种治疗功能性膀胱失调的新组合，其中包括α-激动剂和β-3-肾上腺素受体激动剂。
• Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and an active substance which influences prostaglandin metabolism
  申请人：Wienrich Marion

  公开号：US20050119239A1

  公开（公告）日：2005-06-02

  This invention describes a new combination for the treatment of functional bladder disorders which comprises a beta-3-adrenoceptor agonist and an active substance which influences prostaglandin metabolism.

  本发明描述了一种治疗功能性膀胱失调的新组合，它包括一种β-3肾上腺素受体激动剂和一种影响前列腺素代谢的活性物质。
• Pharmaceutical composition containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha reductase inhibitor
  申请人：Michel Martin

  公开号：US20050101607A1

  公开（公告）日：2005-05-12

  This invention describes a new combination for the treatment of functional bladder disorders which comprises an alpha antagonist and/or 5-alpha-reductase inhibitor and a beta-3-adrenoceptor agonist.
• Pharmaceutical composition comprising beta-3-adrenoceptor-agonists and antimuscarinic agents
  申请人：Wienrich Marion

  公开号：US20050261328A1

  公开（公告）日：2005-11-24

  A pharmaceutical composition useful in the treatment of functional bladder disorders comprising an antimuscarinic agent and a beta-3-adrenoceptor agonist is described.
• Pharmaceutical composition for treating stress incontinence and/or mixed incontinence
  申请人：Michel Martin

  公开号：US20060004105A1

  公开（公告）日：2006-01-05

  This invention describes the use of beta-3-adrenoceptor agonists for the treatment of functional bladder disorders, particularly stress incontinence and/or mixed incontinence.